Last reviewed · How we verify
Monthly antibiotic
Monthly antibiotic is a Antibiotic (long-acting formulation) Small molecule drug developed by CHU de Quebec-Universite Laval. It is currently FDA-approved for Bacterial infections requiring extended-duration therapy. Also known as: Zithromax and cipro.
A monthly antibiotic that provides extended-duration antimicrobial coverage through sustained-release formulation or long-acting delivery.
A monthly antibiotic that provides extended-duration antimicrobial coverage through sustained-release formulation or long-acting delivery. Used for Bacterial infections requiring extended-duration therapy.
At a glance
| Generic name | Monthly antibiotic |
|---|---|
| Also known as | Zithromax and cipro |
| Sponsor | CHU de Quebec-Universite Laval |
| Drug class | Antibiotic (long-acting formulation) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
This marketed antibiotic is formulated for monthly dosing, likely utilizing depot or sustained-release technology to maintain therapeutic drug levels over an extended period. This reduces dosing frequency compared to standard antibiotics while maintaining bactericidal or bacteriostatic activity against susceptible pathogens.
Approved indications
- Bacterial infections requiring extended-duration therapy
Common side effects
- Injection site reactions
- Gastrointestinal disturbances
- Allergic reactions
Key clinical trials
- Durability of Three Monthly Loading Doses With Faricimab in Treatment-naïve Neovascular Age-related Macular Degeneration
- CARNIVAL Study: Gut Flora Dependent Metabolism of Dietary CARNItine and Phosphatidylcholine and cardioVAscuLar Disease (EARLY_PHASE1)
- Polyurethane Foam Versus Gauze Dressing After Cesarean Delivery in a Standardized Surgical Setting: A Prospective Randomized Controlled Trial (NA)
- An Adaptive Multi-arm Trial to Improve Clinical Outcomes Among Children Recovering From Complicated SAM (PHASE3)
- Assess the Efficacy of OM-89 vs Placebo in Reducing Antibiotic Consumption Associated With the Treatment of Urinary Tract Infections in Patients With Neurogenic Bladder (PHASE3)
- Assessment of Masseter Muscle With Ultrasonography (NA)
- Antibiotyping and Prevalence of Virulent Genotypes Among Helicobacter Pylori and Their Impact on Response to Therapy (NA)
- Effect of Pleuran on the Clinical Course of Patients With Chronic Rhinosinusitis (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Monthly antibiotic CI brief — competitive landscape report
- Monthly antibiotic updates RSS · CI watch RSS
- CHU de Quebec-Universite Laval portfolio CI
Frequently asked questions about Monthly antibiotic
What is Monthly antibiotic?
How does Monthly antibiotic work?
What is Monthly antibiotic used for?
Who makes Monthly antibiotic?
Is Monthly antibiotic also known as anything else?
What drug class is Monthly antibiotic in?
What development phase is Monthly antibiotic in?
What are the side effects of Monthly antibiotic?
Related
- Drug class: All Antibiotic (long-acting formulation) drugs
- Manufacturer: CHU de Quebec-Universite Laval — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Bacterial infections requiring extended-duration therapy
- Also known as: Zithromax and cipro
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing